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Spinocerebellar ataxia type 1 (SCA1) is one of
several neurodegenerative diseases caused
by expansion of a polyglutamine tract in the
disease protein, in this case, ATAXIN-1
(ATXN1). A key question in the field is whether
neurotoxicity is mediated by aberrant, novel
interactions with the expanded protein or
whether its wild-type functions are augmented
to a deleterious degree. We examined soluble
protein complexes from mouse cerebellum
and found that the majority of wild-type and
expanded ATXN1 assembles into large stable
complexes containing the transcriptional re-
pressor Capicua. ATXN1 directly binds Capicua
and modulates Capicua repressor activity in
Drosophila and mammalian cells, and its loss
decreases the steady-state level of Capicua.
Interestingly, the S776A mutation, which abro-
gates the neurotoxicity of expanded ATXN1,
substantially reduces the association of mutant
ATXN1with Capicua in vivo. These data provide
insight into the function of ATXN1 and suggest
that SCA1 neuropathology depends on native,
not novel, protein interactions.
INTRODUCTION
SCA1 (Spinocerebellar ataxia type 1) is one of nine unre-
lated genes in which expansion of a glutamine-encodingCell 1triplet repeat causes a dominantly inherited neurodegen-
erative disease. Despite broad expression of polyglut-
amine proteins, distinct subsets of neurons are vulnerable
in each disease. Genetic studies have shown that expan-
sion of the polyglutamine tract confers a toxic gain of func-
tion (Duyao et al., 1995; Ikeda et al., 2005; Matilla et al.,
1998; Matsumoto et al., 2005; Nasir et al., 1995; Zeitlin
et al., 1995). The nature of this gain of function has, how-
ever, remained mysterious. While it is clear that polyglut-
amine tract expansion alters the conformation of soluble
mutant proteins and decreases protein solubility leading
to aggregation (Ross and Poirier, 2004), there is consider-
able debate as to the biophysical and biochemical state of
the disease protein that renders it neurotoxic and the
mechanism that leads to selective neuronal vulnerability
in each of these disorders.
Emerging data reveal that neurotoxicity is modulated
by the context of the polyglutamine expansion. For ex-
ample, the S776A mutation of polyglutamine-expanded
ATAXIN-1 (ATXN1) prevents the ataxia and neurodegener-
ation caused by expression of the SCA1 disease protein in
mouse Purkinje cells (Emamian et al., 2003). Likewise, in
Huntington disease, phosphorylation, SUMO modifica-
tion, or mutation of the Caspase-6 cleavage site modulate
the neurotoxicity of mutant Huntingtin (Graham et al.,
2006; Luo et al., 2005; Pardo et al., 2006; Rangone
et al., 2004; Steffan et al., 2004; Warby et al., 2005).
Full-length, but not truncated, polyglutamine-expanded
androgen receptor reproduces the sex-specific neuropa-
thology of SBMA (Chevalier-Larsen et al., 2004; Katsuno
et al., 2002; McManamny et al., 2002). The discovery
that the AXH domain of ATXN1 mediates SCA1 neuro-
toxicity further emphasized the importance of cis-acting27, 1335–1347, December 29, 2006 ª2006 Elsevier Inc. 1335
domains in pathogenesis and the relationship between
such domains and the polyglutamine tract (Tsuda et al.,
2005). Lastly, studies from Huntington and SCA3 models
have revealed a genetic interaction between the wild-
type proteins and their polyglutamine-expanded counter-
parts (Cattaneo et al., 2005; Van Raamsdonk et al., 2005;
Warrick et al., 2005; Zuccato et al., 2003). These observa-
tions suggest a relationship between the selective neuro-
toxic properties of the polyglutamine-expanded protein
and the normal functions of the wild-type protein.
Aberrant protein interactions are thought to mediate
neurotoxicity in polyglutamine diseases (Gatchel and
Zoghbi, 2005; Harjes and Wanker, 2003; Li and Li, 2004;
MacDonald, 2003). Polyglutamine expansion alters the
interactions of Huntingtin with HAP1/p150Glued/dynein
complexes, as well as numerous transcription factors,
leading to their functional impairment (Chen-Plotkin
et al., 2006; Dunah et al., 2002; Gauthier et al., 2004; Kegel
et al., 2002; Li et al., 2002; Schaffar et al., 2004; Zhai et al.,
2005; Zuccato et al., 2003). Other examples of altered
protein-protein interactions include Ataxin-7 with CRX
and the STAGA/TFTC complexes and Ataxin-3 with com-
ponents of the ubiquitin proteasome system (Chen et al.,
2004; Doss-Pepe et al., 2003; Helmlinger et al., 2006;
McMahon et al., 2005; Palhan et al., 2005; Strom et al.,
2005; Warrick et al., 2005). Nevertheless, it is unknown
if neurotoxicity of the mutant proteins occurs through
associations with these native protein complexes, loss
of these associations, or aberrant interactions and novel
complexes formed by misfolded or aggregating disease
protein.
To test the hypothesis that polyglutamine expansion
mediates pathology by modulating the native protein in-
teractions of the disease protein, we sought to character-
ize the endogenous ATXN1 protein complexes in mouse
cerebellum and identify ATXN1-associated proteins by
biochemical copurification from stable cell lines. We
report that ATXN1 isolated from mouse cerebellum pre-
dominantly associates into large complexes containing
the mammalian homolog of Drosophila Capicua (CIC),
a transcriptional repressor containing a Sox-like high
mobility group (HMG) box. Both major isoforms of CIC
(CIC-L and CIC-S) are subunits of these complexes. We
demonstrate that expression of polyglutamine-expanded
ATXN1 alters the repressor activity of CIC, establishing
a functional link between the two proteins. Finally, we pro-
vide evidence that SCA1 neuropathology depends on
incorporation of polyglutamine-expanded ATXN1 into its
native CIC-containing complexes.
RESULTS
ATXN1 and CIC Associate into Large
Protein Complexes
To identify the major ATXN1 protein complexes in vivo, we
examined soluble ATXN1-associated complexes in wild-
type mouse cerebellum using gel-filtration and ion ex-
change chromatography. Gel filtration revealed that the1336 Cell 127, 1335–1347, December 29, 2006 ª2006 Elsevier Imajority of endogenous wild-type ATXN1 (75%) elutes
as large protein complexes (estimated size 1.8 MDa)
(Figures 1A and 1B). Only about 25% of ATXN1 elutes as
smaller protein complexes (observed as a shoulder on
the larger complexes elution profile, estimated size
300 kDa) (Figure 1B, right panel).
To identify proteins that interact with ATXN1 in its native
complexes, we purified ATXN1-associated proteins by
tandem affinity purification (TAP) (Rigaut et al., 1999) and
mass spectrometry (Figure S1). We found two novel in-
teracting proteins with apparent molecular masses of
160 kDa and 250 kDa, both corresponding to the
human homolog of Drosophila Capicua (Cic). Northern
blot analysis of mouse brain RNA for Cic identified two
major transcripts (Figure S5A) corresponding to two Cic
mRNA transcripts predicted to encode proteins of 258
kDa for CIC-L and 164 kDa for CIC-S (Figure S2A). We
also identified these alternatively spliced CICmRNA tran-
scripts for both human and Drosophila (Figures S2A and
S2B). To detect the endogenous CIC protein, we gener-
ated antisera against the common C-terminal region of
the mouse CIC isoforms (Figure S3A). This antibody spe-
cifically recognized CIC-L andCIC-S frommouse cerebel-
lar and HeLa cell extracts (Figures 1 and S3B).
To determine whether CIC is a stable ATXN1-interacting
partner, we analyzed the elution profile of CIC by gel-filtra-
tion chromatography. We observed that CIC-S and CIC-L
coeluted with the large ATXN1 protein complexes (Figures
1A and 1B). Quantification of the relative elution profiles of
CIC and ATXN1 using 1 ml fractions, which allows the en-
tire profile to be analyzed on a single gel, revealed a near
perfect match between the elution profiles of CIC and the
large ATXN1 complexes (Figure 1B).
If CIC and ATXN1 are components of the same protein
complexes, loss of ATXN1 will alter the elution profiles of
CIC. Indeed, we found that elution of the CIC isoforms is
shifted toward later fractions in cerebellar extracts from
Sca1 null mice (Figure S4). Furthermore, we observed
a strict cofractionation of ATXN1 with the CIC isoforms
using anion exchange chromatography (Figure 1C).
Although no significant population of ATXN1 fractionated
independently of CIC, we did detect low levels of ATXN1
in the flow-through fractions in the absence of detectable
CIC (data not shown), suggesting the smaller ATXN1 com-
plexes have minimal binding to the column matrix.
In sum, the nearly identical elution patterns of the large
ATXN1 complexes with CIC-L and CIC-S, and the shift of
the CIC profiles in the absence of ATXN1, suggest that the
majority of endogenous CIC in the mouse cerebellum sta-
bly associates into ATXN1-CIC protein complexes. Also,
the smaller ATXN1 protein complexes likely do not contain
CIC.
ATXN1 and CIC Interact In Vivo and Colocalize
in the Adult Mouse Brain
To determine whether ATXN1 and CIC interact in the tis-
sue most vulnerable in SCA1, we performed coimmuno-
precipitation (coIP) of cerebellar extracts from wild-typenc.
Figure 1. ATXN1 Forms Complexes with CIC in Wild-Type Mouse Cerebellum
(A) Representative westerns of 0.5ml gel-filtration fractions of wild-type mouse cerebellar extracts analyzed for ATXN1 and CIC isoforms (CIC-L and
CIC-S).
(B) Representative westerns of 1.0 ml gel-filtration fractions of wild-type cerebellar extracts analyzed for CIC and ATXN1. Right panel illustrates the
elution profiles for each protein plotted as the average percent protein (± standard error) in each fraction from four independent extracts. The total
signal in each fraction (measured by densitometry) is divided by the total signal of that protein in all the fractions to determine the percentages shown
in the panel. The column void volume (Vo), gel-filtration standards thyroglobulin (669 kDa) and ADH (150 kDa), and elution volume (ml) of each
collected fraction are indicated.
(C) Representative westerns of monoQ fractions from wild-type cerebellar extracts analyzed for CIC and ATXN1; the approximate eluting NaCl
concentration of selected fractions and elution volume (ml) of each collected fraction are indicated.and Sca1 null mice using anti-ATXN1 antibody (11NQ).
The anti-ATXN1 antibody specifically immunoprecipitated
both CIC isoforms from cerebellar extracts of wild-type
but not Sca1 null mice, indicating that CIC and ATXN1 in-
teract in vivo (Figure 2A; input and loading controls for this
coIP are in Figure 3A). This is in agreement with our recentCellwork, in which we identified CIC as a binding partner of
ATXN1 in an unbiased yeast two-hybrid screen (Lim
et al., 2006).
Having established theATXN1-CIC interaction,wecom-
pared their expression patterns in mouse brain. Northern
blot analysis showed that the Cic isoforms are highly127, 1335–1347, December 29, 2006 ª2006 Elsevier Inc. 1337
Figure 2. Coexpression and CoIP of CIC
and ATXN1 and Reduction of CIC Protein
Levels in the Absence of ATXN1
(A) Mouse ATXN1 and the two CIC isoforms
coIP from cerebellar extracts of wild-type
(Sca1+/+) but not Sca1 null (Sca1/) mice.
The coIP was performed with anti-ATXN1 anti-
body (11NQ) and immunoblotted with anti-CIC
antibody. Preimmune serum served as the neg-
ative control (input and loading controls are in
Figure 3A).
(B) Immunohistochemistry of adult mouse brain
for ATXN1 (left panel) and CIC (right panel).
Both ATXN1 and CIC are abundant in nuclei
of Purkinje cells (arrowhead). Scale bar =
33.6 mm.
(C) SDS-PAGE of cerebellar extracts from
Sca1+/+ and Sca1/ mice, analyzed by west-
ern blot for CIC-L, CIC-S, wild-type ATXN1
(ATXN1[2Q]), and the control Gapdh.
(D) Graphs show the normalized levels of CIC-L
and CIC-S in cerebellar extracts from Sca1/
versus Sca1+/+ mice; mean relative levels
(wt = 100%) and standard error are shown
(n = 5, t test p < 0.001).
(E) Northern analysis of total RNA extracted
from Sca1+/+ and Sca1/ cerebella, probed
for Cic, Sca1, and Gapdh.expressed in the cerebellum and olfactory bulb (Fig-
ure S5A, upper panel). In situ hybridization of adult mouse
brain for Cic and Sca1 revealed strikingly similar expres-
sion patterns, with high expression in Purkinje cells and in
the hippocampus (Figures S5B–S5I). Immunohistochem-
istry for CIC and ATXN1 also displayed matching protein
expression patterns in most brain regions (data not
shown). Importantly, both proteins are highly expressed
in the nuclei of the Purkinje cells, where polyglutamine-
expanded ATXN1 does the most damage (Figure 2B).
To look for interdependence between CIC and ATXN1,
we examined CIC protein levels in Sca1 null mice. We
found that both CIC isoforms had significantly reduced
levels in Sca1 null mouse cerebellum (Figures 2C and
2D) and cerebrum (data not shown). As the mRNA levels
of the Cic isoforms are unaltered in Sca1 null mice, the
dependency of CIC on ATXN1 is posttranscriptional (Fig-
ure 2E). Thus, CIC is less stable in the absence of
ATXN1 in vivo.
The Majority of CIC Associates with ATXN1 In Vivo
To assess the degree of CIC association with ATXN1 in
vivo, we immunoprecipitated ATXN1 from cerebellar ex-
tracts and measured the codepletion of CIC from the
post-IP supernatants. Both CIC isoforms were substan-
tially depleted following ATXN1 immunodepletion, dem-
onstrating that themajority of endogenous CIC associates
with ATXN1 (Figure 3A). In contrast, the levels of neither
Gapdh (data not shown) or AKT (Figure 3A), an ATXN1 ki-
nase thought to interact transiently with ATXN1 (Chen
et al., 2003), are decreased by ATXN1 immunodepletion.
Averaging data from independent experiments, we ob-1338 Cell 127, 1335–1347, December 29, 2006 ª2006 Elsevierserved that when an average of 72%of ATXN1 is immuno-
depleted, an average of 62% of CIC-L and 56% of CIC-S
are codepleted from the cerebellar extracts. We therefore
estimate that 80% of endogenous CIC associates with
ATXN1 (Figure 3B). The depleted CIC isoforms are found
in the pellet of the immunoprecipitate (see for example
Figure 2A).
A Conserved Domain of CIC Interacts with the AXH
Domain of ATXN1
To establish whether CIC also interacts with mutant forms
of ATXN1, we performed immunoprecipitation on lysates
from HeLa cells transiently transfected with variants of
FLAG-tagged ATXN1 containing 2Q, 82Q, or 82Q with
a S776A mutation (which abolishes the interaction of
ATXN1 with 14-3-3) or 2Q with a deletion of the AXH
domain. We found that both endogenous CIC isoforms
coimmunoprecipitated with each of these ATXN1 variants,
except the one lacking the AXH domain (Figure 3C). We
conclude that the ATXN1-CIC interaction requires the
AXH domain and is independent of 14-3-3 binding.
To identify the domains responsible for interaction be-
tween the two proteins, we performed yeast two-hybrid
interaction assays using a series of ATXN1 and CIC dele-
tion constructs. We found that two N-terminal fragments
of CIC-S (amino acids 1–300 and 1–205) interact with
the C-terminal half of ATXN1 and that the AXH domain
of ATXN1 is sufficient for its interaction with CIC (Fig-
ure 3D). To further map the ATXN1 binding domain of
CIC, we generated serial deletions at the N terminus of
mouse CIC-S for pull-down assays with GST-tagged
full-length wild-type ATXN1 (Figures S6A and S6B). WeInc.
Figure 3. The Majority of CIC Associates with ATXN1 In Vivo
(A) Representative westerns of an immunodepletion experiment of Sca1+/+ and Sca1/ cerebellar extracts before (input) and after either anti-ATXN1
(ATXN1) or preimmune sera (Pre) IP (Post-IP Supernatants). Blots analyzed for CIC-L, CIC-S, ATXN1, and AKT as indicated at left of each panel.
(B) Average percentage and standard deviation of ATXN1, CIC-L, and CIC-S proteins immunodepleted from four independent cerebellar extracts by
anti-ATXN1 IP.
(C) IP of lysates from HeLa cells transfected with variants of FLAG-tagged human ATXN1 containing 2Q (F-ATXN1[2Q]), 82Q (F-ATXN1[82Q]), 82Q
with S776A mutation (F-ATXN1[82Q]S776A), or 2Q with the deletion of AXH domain (F-ATXN1[2Q]DAXH). The coIP was performed with anti-FLAG
conjugated beads and immunoblotted with anti-FLAG for ATXN1 and anti-CIC antibody for the endogenous CIC.
(D) Yeast two-hybrid assays mapping the regions responsible for ATXN1-CIC interaction. AD (activation domain) and DB (DNA binding domain) of
Gal4. Controls are the following: lane 1, negative control (DB and AD vectors alone); and lanes 2–5, positive controls.
(E) Sequence alignment of CIC homologs corresponding to amino acids 28–52 of mouse CIC-S reveals a conserved region indicated as ATXN1BD.narrowed the interaction region to 31 amino acids (amino
acids 16–46) of CIC-S (Figure S6C). Comparison of this
31-amino acid sequence across species revealed a
conserved stretch of eight amino acids present in both
CIC-S and CIC-L isoforms with the consensus sequenceCellWXX(L/I)(V/L)PX(L/M) (Figure 3E). We then confirmed
in vitro that human ATXN1 binds toDrosophilaCic through
the consensus eight amino acids (Figure S6D). ATXN1 and
CIC thus appear to be in vivo binding partners that interact
directly through evolutionarily conserved domains.127, 1335–1347, December 29, 2006 ª2006 Elsevier Inc. 1339
Soluble ATXN1[154Q] and Wild-Type ATXN1
Associate with Similarly Sized Complexes
Having established that polyglutamine-expanded ATXN1
interacts with CIC, we asked whether the expanded poly-
glutamine tract alters the incorporation of ATXN1 into its
native protein complexes. We examined cerebellar ex-
tracts from Sca1154Q/+ animals that express polyglut-
amine-expanded ATXN1[154Q] from its endogenous lo-
cus and are an accurate model of SCA1 (Watase et al.,
2002). As previously reported, the levels of soluble ex-
panded protein are significantly lower than wild-type
ATXN1 levels in these animals, although expression of
the mutant allele is identical to the wild-type allele (Watase
et al., 2002). Gel-filtration chromatography of extracts
from early symptomatic animals (10–15 weeks of age) re-
vealed that soluble ATXN1[154Q] and wild-type ATXN1
(expressed from the untargeted allele) eluted into the
same fractions as ATXN1 from wild-type extracts
(Figure 4A). The elution profile of CIC from Sca1154Q/+
mice is indistinguishable from that seen in wild-type ani-
mals (Figure 4A). A subtle change in the elution profile of
the smaller ATXN1 complexes (elution fractions from 13
ml to 16 ml) was observed in the mutant animals: both
ATXN1[154Q] and wild-type ATXN1 showed a relative
loss from elution fractions at 14ml and beyond, with a cor-
responding increase in elution fractions at 13 ml and 13.5
ml (estimated size 500 kDa) compared to wild-type ani-
mals (compare Figure 1A to 4A). The basis for this change
is unclear at present, but it could represent an alternate
conformation of the smaller ATXN1 protein complexes
coupled with the slight increase of molecular weight due
to polyglutamine expansion. The similar elution patterns
of wild-type and expanded ATXN1 by gel-filtration chro-
matography suggest that polyglutamine expansion does
not prevent the incorporation of ATXN1 into its normal en-
dogenous protein complexes.
To confirm that polyglutamine-expanded ATXN1 incor-
porates into similar complexes as wild-type ATXN1,
we analyzed cerebellar extracts from Sca1154Q/+ animals
by anion-exchange chromatography. We found that
ATXN1[154Q] coelutes with wild-type ATXN1 and with
both CIC isoforms (Figure 4B). The elution profiles of
ATXN1, CIC-L, and CIC-S in extracts by anion-exchange
chromatography are quite broad; this argues against a sin-
gle complex of uniform structure and suggests that the
ATXN1-CIC protein complexes adopt multiple conforma-
tional or compositional states separable by differences
in their charge (Figures 1C and 4B).
The S776A Mutation Reduces Incorporation
of Mutant ATXN1 into the Large
ATXN1-CIC Complexes
We previously showed that mutating serine 776 of ATXN1
to alanine (S776A) dramatically suppresses the neurotox-
icity of the polyglutamine-expanded protein in Purkinje
cells (Emamian et al., 2003). This mutation causes loss
of interaction with the chaperone protein 14-3-3 (Chen
et al., 2003). To investigate whether the decrease in1340 Cell 127, 1335–1347, December 29, 2006 ª2006 Elsevierpathogenicity correlates with alterations in the ATXN1
complexes in vivo, we compared transgenic mice expres-
sing human polyglutamine-expanded ATXN1[82Q] (Tg-
SCA1[82Q]) with transgenic mice expressing ATXN1[82Q]
with the S776A mutation (Tg-SCA1[82Q]S776A)—both
transgenic lines express the ATXN1 variants specifically
in cerebellar Purkinje cells at similar levels (Burright
et al., 1995; Emamian et al., 2003).
We analyzed cerebellar extracts from Tg-SCA1[82Q]
mice by gel filtration and found that ATXN1[82Q] asso-
ciates into both large and small protein complexes
(Figures 4C and 4E). However, cerebellar extracts
from Tg-SCA1[82Q]S776A showed a specific loss of
ATXN1[82Q]S776A from the large protein complexes,
whereas wild-type ATXN1 had an elution profile similar
to wild-type extracts (Figures 4D and 4E). The normal
elution pattern of endogenous wild-type ATXN1 sug-
gested that the elution profile of CIC would be similar in
Tg-SCA1[82Q]S776A and wild-type animals, and this in-
deed was the case. Failure of ATXN1[82Q]S776A to incor-
porate into the large ATXN1-CIC complexes is not due to
a general inability of the S776A mutant protein to physi-
cally bind CIC, as both endogenous CIC isoforms from
HeLa cells can be coimmunoprecipitated with ATXN1, in-
dependent of polyglutamine expansion and/or the S776A
mutation (Figure 3C). This suggests that the S776 residue
of ATXN1 plays a critical role in regulating ATXN1-CIC
complex formation in Purkinje cells.
Human Mutant ATXN1 Blocks Cic Function
in Drosophila
The finding that loss of polyglutamine-expanded ATXN1
from its large native complexes correlates with a lack of
neuronal dysfunction in Tg-SCA1[82Q]S776A suggests
that mutant ATXN1 might cause toxicity by altering the
function of its native complexes. We hypothesized that
polyglutamine-expanded ATXN1 affects the function of
its native complex by interfering with the function of CIC.
To explore this possibility we turned to Drosophila, where
the function of Cic has been investigated in vivo.
We performed genetic interaction studies to determine
whether Cic can modify ATXN1 phenotypes and whether
ATXN1 interferes with the repressor function of Cic
in vivo. We previously showed that expression of human
SCA1[82Q] in the Drosophila eye causes a degenerative
phenotype (Fernandez-Funez et al., 2000). To test whether
Drosophila cicmodifies theSCA1[82Q] eye phenotype, we
generated transgenic flies expressing Drosophila cic. As
expected, flies coexpressing SCA1[82Q] and a control
gene (GFP) at 29C show ommatidial disorganization and
fusion as well as interommatidial bristle loss (Figures 5A
and 5B). Although overexpression of cic also causes mild
ommatidial disorganization (Figure 5D), coexpression of
cic and SCA1[82Q] ameliorates the ommatidial disorgani-
zationof theflyeyeandpartially restoresbristles (Figure5C),
demonstrating that Cic modulates ATXN1’s toxicity.
To examine SCA1[82Q] eye phenotypes in the context
of cic mutations, we crossed SCA1[82Q] flies with cic2Inc.
Figure 4. Polyglutamine-Expanded ATXN1 Associates with CIC in Its Native Complexes unless It Carries the S776A Mutation that
Suppresses Its Toxicity
(A) Representative westerns of 0.5 ml gel-filtration fractions of Sca1154Q/+ mouse cerebellar extracts analyzed for CIC, ATXN1[154Q], and wild-type
ATXN1.
(B) Representative westerns of monoQ fractions from Sca1154Q/+ cerebellar extracts analyzed for CIC, ATXN1[154Q], and wild-type ATXN1.
(C and D) Representative westerns of gel-filtration fractions from Tg-SCA1[82Q] (C) or Tg-SCA1[82Q]S776A (D) cerebellar extracts, analyzed for CIC,
wild-type ATXN1, ATXN1[82Q], or ATXN1[82Q]S776A protein. The large complexes formed by transgenic human ATXN1[82Q] proteins are shifted
toward earlier fractions compared to the mouse ATXN1 complexes, likely due to intrinsic differences between the mouse and human proteins.
The key finding is that the large complexes formed by ATXN1[82Q] are almost absent for ATXN1[82Q]S776A.
(E) Fractionation profiles comparing the mutant ATXN1 proteins analyzed as in (C and D), plotted as the average percent of mutant ATXN1 proteins
(± standard error) in each fraction averaged from two independent extracts of each genotype. The total signal in each fraction (measured by densi-
tometry of the protein band) is divided by the total signal for that protein in all the fractions to determine the percentages shown in the panel.Cell 127, 1335–1347, December 29, 2006 ª2006 Elsevier Inc. 1341
Figure 5. Drosophila Cic Modifies
Human ATXN1[82Q]-Induced Eye Pheno-
types
Overexpression of Drosophila Cic suppresses
ATXN1-induced eye abnormalities.
(A)–(D) Eye scanning electron microscopy
(SEM) of (A) yw; gmr-GAL4/UAS-GFP (control),
(B)UAS-SCA1[82Q]F7/yw;gmr-GAL4/UAS-GFP,
(C) UAS-SCA1[82Q]F7/yw; gmr-GAL4/+;UAS-
cic/+, and (D) gmr-GAL4/UAS-GFP;UAS-cic/+.
ATXN1-induced eye phenotypes are enhanced
in cic2/+ background.
(E)–(G) Eye SEM of (E) UAS-SCA1[82Q]F7/yw;
gmr-GAL4/UAS-GFP, (F) UAS-SCA1[82Q]F7/
yw; gmr-GAL4/+; cic2/+, and (G) gmr-GAL4/
UAS-GFP; cic2/+. Flies from (A)–(D) were raised
at 29C and (E)–(G) at 25C. Scale bar = 10 mm.mutant flies, an EMS-induced null allele (Roch et al., 2002).
At room temperature,SCA1[82Q] flies showmilder omma-
tidial disorganization due to decreased expression of the
disease protein (Figure 5E). But loss of one functional al-
lele of cic, which by itself causes no eye phenotype, wors-
ened ommatidial disorganization in these SCA1[82Q] flies
(compare Figure 5E to 5F).
In Drosophila, Cic functions as a transcriptional regula-
tor important for various developmental processes (Atkey
et al., 2006; Jimenez et al., 2000; Roch et al., 2002). In the
developing wing, Cic represses several wing-vein specific
genes, argos (aos), ventral veinless (vvl), and decapenta-
plegic (dpp), and cic mutants develop ectopic and thick-
ened wing veins (Roch et al., 2002). This provided an
excellent opportunity to study the effects of ATXN1 on
Cic’s endogenous repressor function, because expres-
sion of human SCA1[82Q] and Drosophila Atxn1 in the
wing also causes wing-vein phenotypes (Tsuda et al.,
2005).
Using a wing-pouch specific driver (C5-GAL4) to
express SCA1[82Q], we observed smaller wings with a
thicker L3 vein, a missing posterior crossvein, and ectopic
vein formation (Figure 6A). These phenotypes were more
prominent at the posterior part of the wing, where the ex-
pression of the transgene was highest (Figure 6N). The
higher expression of SCA1[82Q] in males (due to insertion
of the transgene on the X chromosome) produced atro-1342 Cell 127, 1335–1347, December 29, 2006 ª2006 Elsevierphic wings (Figure 6E). Animals heterozygous for the cic2
null allele (cic2/+) did not show a wing phenotype (Fig-
ure 6C), but C5-GAL4-driven expression of SCA1[82Q]
in the cic2/+ background showed more prominent L3
vein thickening and increased ectopic vein formation in
the posterior part of the interveins than overexpression
of SCA1[82Q] alone (Figures 6A and 6B).
Because mutant ATXN1-induced wing-vein abnormali-
ties were augmented in the cic2/+ background, we tested
whether increasing Cic levels could suppress these phe-
notypes. Although cic overexpression caused the loss of
veins at the posterior part of the wing (Figures 6G and
6K), as predicted from its role in wing-vein development,
it restored overall wing integrity in flies expressing
SCA1[82Q] (compare Figure 6E to 6F and Figure 6I to
6J). Importantly, flies overexpressing SCA1[82Q]DAXH
did not develop these wing abnormalities (Figure 6H).
This demonstrates that SCA1[82Q] wing-vein phenotypes
are dependent on the AXH domain, supporting our finding
that this domain mediates ATXN1-CIC interactions.
Therefore, the mutant ATXN1-induced wing-vein abnor-
malities are likely acting via the cic pathway.
To confirm that SCA1[82Q] modifies cic pathway func-
tion, we examined the expression of a cic downstream tar-
get gene, aos, using an aos-promoter LacZ reporter line
(aosW11). In the wild-type pupal wing at 36 hr after pupar-
ium formation (APF), the expression of aos was confinedInc.
Figure 6. Genetic Interaction of Drosophila cic and Human ATXN1[82Q] in Drosophila Wing
Wing abnormality phenotypes of SCA1[82Q] transgenic flies are modified by hypomorphic and transgenic alleles of cic; representative wings are
shown for each genotype.
(A)–(D) A strong hypomorphic allele of cic (cic2) enhances human ATXN1-induced wing-vein abnormalities under the control of C5-GAL4 driver. In (A)
is the following: UAS-SCA1[82Q]/+; C5-GAL4/+ flies show thickening of L3 vein (arrow), extra veins formation (arrowhead), and a missing posterior
crossvein (*). In (B) is the following: UAS-SCA1[82Q]/+; C5-GAL4/cic2 transgenic flies display further thickening of the L3 vein (arrow) and increased
extra vein formation (arrowhead). Controls UAS-GFP/+; C5-GAL4/cic2 (C) and UAS-GFP/+; C5-GAL4/+ (D) show a normal wing phenotype.
(E)–(K) The UAS-cic flies (Tgcic) suppress ATXN1-induced wing abnormalities. In (E) is the following: male wing of UAS-SCA1[82Q]/Y; UAS-GFP/+;
C5-GAL4/+ and (I) female wing of UAS-SCA1[82Q]/+; UAS-GFP/+; C5-GAL4/+ show dosage dependent phenotypes of the wing abnormalities and
both are suppressed by overexpression of cic (F and J). Both male (G) and female (K) UAS-GFP/UAS-cic; C5-GAL4/+ show missing veins (arrow-
heads) and crossvein (*) phenotype. (H) AXH deletion in UAS-SCA1[82Q]DAXH/+; C5-GAL4/+ flies abolishes the wing abnormality induced by the
polyglutamine expansion.
(L)–(M)ATXN1[82Q] derepressesaosexpression. LacZstainingof36hrAPFwingsofaosw11/C5-GAL4 (L) andUAS-SCA1[82Q]/+;aosw11/C5-GAL4 (M).
(N) Immunofluorescence staining for ATXN1 of UAS-SCA1[82Q]/+; aosw11/C5-GAL4 wing at 36 hr after puparium formation. Scale bar = 268 mm.to the vein region as shown by LacZ staining (Figure 6L). In
contrast, aos expression was derepressed in flies
expressing SCA1[82Q] in the wing pouch under the con-
trol of the C5-GAL4 driver (Figure 6M). Furthermore, ex-
pansion of the aos expression domain correlated with
the expression of SCA1[82Q] (Figure 6N). These data indi-
cate that overexpression of ATXN1[82Q] impairs Cic func-
tion, probably through direct protein-protein interactions,
relieving aos repression by Cic.
Differential Effects of Wild-Type and Mutant ATXN1
on CIC Transcriptional Repression
Having established that mutant ATXN1 interferes with the
function of Cic as a repressor in Drosophila, we asked
whether ATXN1 affects the function of CIC in amammalian
system. We performed luciferase assays using a reporter
construct bearing six copies of the recently identified CIC
binding site (CBS) (Kawamura-Saito et al., 2006). We ob-Cell 1served a moderate decrease in luciferase activity when
HEK293T cells were transfected with a small amount
(2.5 ng) of CIC-S, whereas coexpression with ATXN1[2Q]
decreased luciferase activity 2-fold (Figure 7). The syner-
gistic effect of ATXN1 and CIC-S coexpression on the
transcriptional repression activity of CIC-S required the
AXH domain. Interestingly, the ability of ATXN1[82Q] to
repress transcription was impaired in comparison with
ATXN1[2Q] only when CIC-S was cotransfected (Figure 7).
These data demonstrate a direct link between the tran-
scriptional repression activities of CIC and ATXN1 and
show that polyglutamine expansion alters functions that
depend on the interaction of these proteins.
DISCUSSION
The data presented in this study demonstrate that the ma-
jority of cerebellar ATXN1 associates into a group of large27, 1335–1347, December 29, 2006 ª2006 Elsevier Inc. 1343
Figure 7. Synergistic Repression of
Luciferase Activity by ATXN1 and CIC
HEK293T cells transfected with a luciferase re-
porter that has CIC binding sites and expres-
sion plasmids (CIC-S and ATXN1 variants) in
duplicate. The luciferase data are expressed
as mean percentage of luciferase activity
(± standard error) relative to the reporter alone
(nR 4, t test * p < 0.05 and ** p < 0.005).complexes that contain the transcriptional repressor CIC.
We found that a nonpathogenic form of polyglutamine-
expanded ATXN1, the S776A mutant, does not associate
with the large ATXN1-CIC complexes, indicating that in-
corporation of polyglutamine-expanded ATXN1 into these
complexes is important for its toxicity. Our findings that
the majority of endogenous CIC associates with ATXN1
and that CIC levels are decreased in the absence of
ATXN1 underscore the functional relationship between
these two proteins. Lastly, we demonstrate that polyglut-
amine-expanded ATXN1 alters the repressor activity of
CIC in vitro and in vivo. We conclude that ATXN1 acts
in a transcriptional repressor complex and that polyglut-
amine-expanded ATXN1 exerts neurotoxicity through
its native complexes containing CIC rather than through
aberrant interactions with novel proteins. The comple-
mentary approaches we have taken permitted us to go
beyond the identification of binary protein-protein inter-
actions and to elucidate pathologically relevant alter-
ations in native protein complexes harboring the disease
protein.
Previous work from our lab and others has identified
several ATXN1-interacting proteins and genetic modifiers
of SCA1 phenotypes that are involved in transcriptional
regulation, including silencing mediator of retinoid and
thyroid hormone receptors (SMRT), polyglutamine binding
protein 1 (PQBP1), and growth factor independent-1
(Gfi-1) (Fernandez-Funez et al., 2000; Okazawa et al.,
2002; Tsai et al., 2004; Tsuda et al., 2005). It remains
unknown, however, whether these proteins form stable
complexes or transiently interact with ATXN1. For exam-
ple, the interaction of ATXN1with the Senseless/Gfi-1 pro-
teins leads to their destabilization and is expected to be
transient (Tsuda et al., 2005). Consistent with this, we
did not find mouse Gfi-1 or SMRT associated with the
major ATXN1 complexes in vivo (data not shown).
CIC contains a Sox-like high mobility group (HMG) box
and likely acts as a transcriptional repressor (Atkey et al.,
2006; Jimenez et al., 2000; Roch et al., 2002). Given that1344 Cell 127, 1335–1347, December 29, 2006 ª2006 Elsevier IATXN1 lacks sequence-specific DNA binding activity (de
Chiara et al., 2005), CIC could be involved in directing
ATXN1 to gene targets for repression. Our studies
clearly show that ATXN1 has a synergistic effect on
the transcriptional repressor activity of CIC that is par-
tially compromised by the polyglutamine expansion.
One possible explanation is that polyglutamine expan-
sion alters the conformational state of the ATXN1 pro-
tein, which in turn alters the conformational or functional
state of the ATXN1-CIC complex. Identifying transcrip-
tional targets of the ATXN1-CIC complexes, particularly
in the selectively vulnerable Purkinje cells, will likely
reveal specific pathways that are critical for disease
pathogenesis.
Our findings for SCA1may apply to other polyglutamine
diseases. Indeed, altered interactions of mutant Hunting-
tin with HAP1 and p150Glued have been associated with
impaired axonal trafficking of BDNF (Gauthier et al.,
2004). Thus, changes in native complexes could be one
of the final steps of commonality in polyglutamine disease
pathogenesis. Beyond this step, we suggest that the fea-
tures particular to each disease are determined by both
transient and stable protein interactions and the suscepti-
bility of such interactions to conformational or functional
alterations by the soluble polyglutamine-expanded dis-
ease protein. Determining how polyglutamine expansion
alters the activity of the disease protein could enable ther-
apeutic approaches to counter neuropathology by either
blocking specific interactions that mediate selective neu-
rotoxicity or modulating the downstream events of such
interactions. Beyond polyglutamine diseases, it is becom-
ing clear that elevated levels of even wild-type amyloid
precursor protein and wild-type a-synuclein cause
dementia and Parkison disease, respectively, just as over-
expression of wild-type ATXN1 produces neurodegenera-
tion (Eriksen et al., 2005; Fernandez-Funez et al., 2000;
Rovelet-Lecrux et al., 2006). Identifying these native pro-
tein complexes could point to key effectors or modifiers
of the disease phenotypes.nc.
EXPERIMENTAL PROCEDURES
Column Fractionation and Analysis
Chromatography was carried out at 4C using the Amersham Pharma-
cia LCC-500 FPLC system. Unless stated otherwise, the data shown
represent >10 independent runs for each genotype analyzed. Cerebel-
lar extracts were prepared fresh by dounce homogenization of one to
two cerebella from age-matched mice (%16 weeks) dissected in TST
buffer (50mM Tris, pH 8, 75mM NaCl, 0.5% Triton X-100, 1mM PMSF,
and protease inhibitors). Seven hundred microliters were loaded for
FPLC. Gel filtration was a Superose 6 10/300 GL column (Amersham
Pharmacia) equilibrated in buffer (50 mM Tris, pH 8, 20mM NaCl) at
0.4 ml/min. Fractions were collected every 0.5 ml or 1 ml volume, col-
umn void volume was 7.7ml, and elution volumes of gel-filtration stan-
dards were 12.4 ml for thyroglobulin (669 kDa), 15.8 ml for ADH
(150 kDa), and 19.2ml for cytochrome C (12.4 kDa). Anion exchange
was a MonoQ 5/5 HR column (Amersham Pharmacia) equilibrated in
buffer (50 mM Tris, pH 8, 50 mM NaCl); after washing the column
with 13 column volumes of the same buffer, bound proteins were
eluted by a 20 ml linear NaCl salt gradient from 50 mM to 600 mM
NaCl in 50 mM Tris, pH 8 at 1ml/min; 1 ml fractions were collected.
All fractions were supplemented with protease inhibitors and immedi-
ately prepared for SDS-PAGE.
Immunoprecipitation
Protein (0.5 mg) from cerebellar extracts in 200 ml TST buffer were
diluted with 800 ml of cold PBS (Input). Two microliters of Anti-
ATXN1 (11NQ) serum or preimmune serum was added and incubated
overnight at 4C. IP was performed with BSA-blocked protein G
sepharose beads, and the immunodepleted supernatant (Post-IP
Supernatant) was saved, and the pellet (IP pellet) was resuspended
in sample buffer following three to six washes with cold PBS. Input,
post-IP supernatant, and IP pellets were analyzed by SDS-PAGE
and western blot.
RNA and Protein Analyses
RNA isolation and northern blot was as described (Emamian et al.,
2003). The Gapdh probe is a 486 bp PCR fragment of the mouse
cDNA; the Cic probe is a 530 bp SpeI fragment of the coding region
common to both isoforms, and the Sca1 probe is as clone correspond-
ing to mouse cDNA.
Guinea pig polyclonal anti-CIC serum was generated by immunizing
with bacterially expressed HIS-tagged C-terminal 214 amino acids of
CIC (Cocalico). Mouse monoclonal anti-FLAG M2 (Sigma), rabbit
polyclonal anti-ATXN1 (11750VII and 11NQ), mouse monoclonal anti-
GAPDH (Advance Immunochemical), and rabbit polyclonal anti-AKT
(Cell Signaling) were used. SDS-PAGE western blotting and immuno-
histochemistry followed standard protocols (Chen et al., 2003; Watase
et al., 2002). Yeast two-hybrid assay was performed as previously
described (Lim et al., 2006).
Fly Strains
Drosophila cic cDNA was inserted in the pUAST vector to generate
UAS-cic transgenic lines. Other strains used were UAS-SCA1[82Q] (F7,
N35Y, M6) (Fernandez-Funez et al., 2000), UAS-SCA11[82Q]DAXH
(Tsuda et al., 2005), C5-GAL4 (Yeh et al., 1995), UAS-GFP (H. Bellen),
cic2 (Roch et al., 2002), aosW11, and yw (Bloomington stock center).
X-Gal Staining and SEM
Thirty-six hour APF pupae were fixed in 0.3% glutaraldehyde solution
for 10 min. The pupal wings were dissected in 1XPBS and washed in
1XPBS for 15–30 min before staining in 0.3% X-gal in Fe/NaP solution
for 3 hr at 37C. Processing of Drosophila for SEM was performed as
previously described (Fernandez-Funez et al., 2000). Image acquisi-
tion was taken from MD Anderson SEM core.Cell 1Luciferase Assay
Cotransfected were 1.8 3 105 HEK293T cells in 24-well plates using
Lipofectamine 2000 (Invitrogen) with 50 ng of the pGL3-Promoter
(Promega) containing six copies of CIC binding sites (TGAATGAA or
TGAATGGA) (Kawamura-Saito et al., 2006), 10 ng of pRL-TK, and
2.5 ng of expression plasmids as indicated. The total amount of DNA
transfected was kept constant by adding pcDNA3.1() (Invitrogen).
Luciferase activities were measured using the dual luciferase reporter
assay system (Promega).
Supplemental Data
Supplemental Data include six figures and Supplemental References
and can be found with this article online at http://www.cell.com/cgi/
content/full/127/7/1335/DC1/.
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